+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

From
From
From
Cancer Therapeutics Market Report and Forecast 2023-2031 - Product Thumbnail Image

Cancer Therapeutics Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Cancer Immunotherapy Market Report and Forecast 2023-2031 - Product Thumbnail Image

Cancer Immunotherapy Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Immuno-oncology Market - Product Thumbnail Image

Immuno-oncology Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Checkpoint kinase inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint kinase inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 90 Pages
  • Global
From
Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Hematopoietic progenitor kinase 1 inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
From
Immunotherapy Drugs Market 2024-2028 - Product Thumbnail Image

Immunotherapy Drugs Market 2024-2028

  • Report
  • November 2023
  • 163 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more